HCAT Stock Forecast & Price Target

Health Catalyst is attractive because management’s FY26 bookings guide of $22M–$26M, alongside Q1 described as strong with positive momentum into Q2, suggests demand remains healthy despite a pressured hospital purchasing environment. The company also appears to be improving its cost structure through Project Nexus, which targets about $30M of annualized run-rate savings, while its existing-customer expansion model is compelling since selling into established accounts is said to be more than 2x more effective. Although competition is intense and the new TEMS contracts dilute margins initially, the scale of the platform, higher mix of repeat business, and potential upside from new booking metrics support a constructive long-term view.

Health Catalyst is facing a difficult reset as the Vitalware divestiture removed a meaningful earnings contributor and exposed the core business to churn and down-sell risk, especially among DOS clients. Although 2Q revenue of $70.5 million and adj.-EBITDA of $9.9 million beat expectations, FY26 guidance fell to $260 million–$265 million of revenue and $30 million–$33 million of adj.-EBITDA, signaling a sharp second-half step-down tied to migration and retention pressure. Management also sees a ~$52 million DOS-related ARR pool still at risk across FY26 and FY27, while a tougher hospital spending environment, longer sales cycles, and a more services-heavy mix threaten both growth and margins.